ANI PHARMACEUTICALS, INC
Moat Score — ANI Pharmaceuticals, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Cortrophin Gel's complex, biologic-like manufacturing process derived from porcine pituitary extraction creates genuine, hard-to-replicate production know-how that meaningfully limits direct generic competition, unlike most of ANI's small-molecule generic portfolio. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | ANI's vertically integrated manufacturing supports some cost control, but as a mid-cap specialty pharma company it lacks the scale cost advantages of larger diversified generic manufacturers like Teva and Viatris. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Cortrophin Gel's manufacturing complexity and position as an alternative to Mallinckrodt's Acthar Gel give ANI real pricing power in that specific therapeutic category, even as its base generics business faces typical commodity pricing pressure. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical manufacturing and distribution exhibit no network effect; the value of ANI's products to one customer does not increase because other customers also purchase them. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physicians and patients stabilized on Cortrophin Gel for chronic autoimmune or inflammatory conditions face some switching friction given treatment continuity concerns, while ANI's generic products face minimal switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The complex manufacturing requirements for corticotropin gel products naturally limit the number of viable competitors to essentially ANI and Mallinckrodt, giving ANI real efficient-scale protection within that specific niche, even though its broader generics business remains highly competitive. |